KPV peptide references and CAS number
These sources concern KPV peptide identity, inflammatory signaling, animal outcomes, and regulatory questions. Each note identifies what the source contributes, rather than treating every paper as evidence of a human benefit. The collection includes both direct experiments and broader reviews. It contains no published clinical trial establishing standalone KPV treatment in people.
KPV peptide CAS number and chemical identity
The CAS number recorded for unmodified KPV is 67727-97-3. Its sequence is H-Lys-Pro-Val-OH, and its formula is C16H30N4O4. The research record lists a molecular weight of approximately 342.44 Da. These identify the tripeptide discussed here; salt forms and altered molecules require separate attention.
The FDA's 2026 chemical and safety assessment describes naming differences between KPV free base, acetate, and other derivatives. An identifier establishes neither the quality of a particular batch nor its suitability for human use. The FAQ separates those questions.
Intestinal uptake and colitis experiments
Dalmasso and colleagues, 2008, Gastroenterology studied PepT1-mediated uptake, inflammatory signaling in intestinal and immune cells, and oral KPV in mouse colitis. This is the central source for the cell concentration and drinking-water exposure discussed on the dosage page. Its human-derived cell lines do not make it a human clinical study. DOI: 10.1053/j.gastro.2007.10.026.
Kannengiesser and colleagues, 2008, Inflammatory Bowel Diseases examined recovery and inflammatory changes in mouse colitis, including mice with impaired MC1R. It contributes a separate animal result and a question about receptor dependence. Neither the species nor the induced disease can be omitted when describing its findings. DOI: 10.1002/ibd.20334.
Signaling and the hormone relationship
Getting, Schiöth, and Perretti, 2003, Journal of Pharmacology and Experimental Therapeutics compared hormone fragments in mouse inflammation and cultured macrophages. KPV's effects differed across the measurements. The paper supports a more specific account than a single claim about suppressing all inflammatory signals. DOI: 10.1124/jpet.103.051623.
Brzoska and colleagues, 2008, Endocrine Reviews reviewed alpha-MSH and smaller related peptides across experimental inflammatory settings. It supplies background on KPV's relationship to the larger hormone and its lack of pigmentary action in that literature. A review summarizes existing evidence; it is not an additional treatment trial. DOI: 10.1210/er.2007-0027.
Bohm and colleagues, 2004, Journal of Investigative Dermatology examined hormone-related signaling in human keratinocytes. It provides skin-cell context for the mechanism discussion. These cells were studied in laboratory conditions, leaving delivery through skin and clinical outcomes as separate questions. DOI: 10.1111/j.0022-202X.2004.22404.x.
Formulation and related chemistry
Xiao and colleagues, 2017, Molecular Therapy tested targeted KPV nanoparticles in a hydrogel for mouse colitis. The carrier and its comparison group are essential to understanding the outcome. The paper does not establish equivalent delivery from every preparation taken orally. DOI: 10.1016/j.ymthe.2016.11.020.
Zhang and colleagues, 2024, Frontiers in Pharmacology studied a co-assembled KPV/FK506 nanodrug in acute and chronic mouse colitis. Because FK506 is another active agent, the combination's results cannot all be credited to KPV. Its preparation differs from the free peptide and from other blends. DOI: 10.3389/fphar.2024.1442876.
Dettin and colleagues, 2018, PLoS One synthesized and characterized KPV analogs modified at lysine. This chemistry helps distinguish the starting tripeptide from altered compounds. It provides no clinical comparison establishing the safety or effectiveness of those analogs. DOI: 10.1371/journal.pone.0199686.
Corneal repair
Bonfiglio and colleagues, 2006, Experimental Eye Research studied topical KPV after experimental corneal injury in rabbits, with related cell work. It is the source for the rabbit regimen and the 60-hour surface-restoration finding. Its eye-tissue result cannot establish a human healing timetable. DOI: 10.1016/j.exer.2006.07.014.
FDA documents and compounding context
The FDA's 2026 KPV assessment addresses chemistry, exposure data, toxicity gaps, and the proposed compounding uses. The FDA safety-risk page, current as of April 22, 2026, records the withdrawn nomination while retaining its safety concerns. That date belongs to the page, not a dated move for KPV.
The FDA also explains what compounding involves and how bulk ingredients are considered under 503A. These sources support the distinction between a prescription, ingredient eligibility, and drug approval. The legal-status page follows those distinctions and the recorded committee recommendation.
The HHS draft policy, published October 30, 2026, describes the department's intent not to take enforcement action against state-licensed pharmacies and licensed physicians compounding KPV alone for an individual patient's prescription under set conditions. It confers no FDA approval; KPV is still absent from FDA's 503A bulks list. Blends and 503B outsourcing facilities fall outside its scope. The draft reports a July 2026 committee recommendation to add KPV despite FDA staff's recommendation against it, with no published vote count. Federal Register 91 FR 68526; docket HHS-OASH-2026-0496.
